Published in Heart Fail Clin on October 18, 2012
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation (2016) 1.43
Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations. Stat Med (2014) 0.76
Cardiac neuronal imaging with ¹²³I-meta-iodobenzylguanidine in heart failure: implications of endpoint selection and quantitative analysis on clinical decisions. Eur J Nucl Med Mol Imaging (2014) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
What is value in health care? N Engl J Med (2010) 17.15
Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 14.01
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA (2006) 11.87
Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med (1989) 11.07
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med (2004) 10.02
Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med (2009) 7.71
Cardiorenal syndrome. J Am Coll Cardiol (2008) 7.09
HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail (2010) 6.37
Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA (2005) 6.10
Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol (2000) 6.08
A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol (1989) 5.50
Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA (2002) 5.19
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19
More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail (2001) 4.29
Utilities and quality-adjusted life years. Int J Technol Assess Health Care (1989) 4.18
Utility approach to measuring health-related quality of life. J Chronic Dis (1987) 3.92
Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA (2005) 3.37
Quality, innovation, and value for money: NICE and the British National Health Service. JAMA (2005) 3.36
Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J (2005) 3.26
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ (2007) 3.06
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA (2007) 2.90
Comparative effectiveness and health care spending--implications for reform. N Engl J Med (2010) 2.81
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78
Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med (2010) 2.71
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol (1993) 2.15
Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol (2006) 1.98
Changing preferences for survival after hospitalization with advanced heart failure. J Am Coll Cardiol (2008) 1.96
Consensus statement: Palliative and supportive care in advanced heart failure. J Card Fail (2004) 1.95
Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant (2001) 1.92
Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung (2002) 1.85
Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart (2006) 1.84
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation (2009) 1.82
Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol (2010) 1.80
Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs. Health Aff (Millwood) (2008) 1.74
Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation (2010) 1.72
Choice of clinical outcomes in randomized trials of heart failure therapies: disease-specific or overall outcomes? Am Heart J (2002) 1.64
Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation (2004) 1.63
Evolving applications for patient-centered health status measures. Circulation (2008) 1.57
Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol (2005) 1.42
Economic burden of heart failure in the elderly. Pharmacoeconomics (2008) 1.34
Management of acute decompensated heart failure. CMAJ (2007) 1.33
A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J (2008) 1.33
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J (2008) 1.24
Identifying heart failure patients at high risk for near-term cardiovascular events with serial health status assessments. Circulation (2007) 1.24
Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med (2001) 1.17
A comparison of death certificate out-of-hospital coronary heart disease death with physician-adjudicated sudden cardiac death. Am J Cardiol (2005) 1.16
End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol (2009) 1.13
A global ranking approach to end points in trials of mechanical circulatory support devices. J Card Fail (2008) 1.05
A global rank end point for clinical trials in acute heart failure. Circ Heart Fail (2010) 1.01
Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease. Am Rev Respir Dis (1987) 1.01
Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). Am Heart J (2002) 1.00
Generic and disease-specific quality of life as a predictor of long-term mortality in heart failure. Eur J Heart Fail (2010) 0.98
Thresholds of physical activity and life expectancy for patients considering destination ventricular assist devices. J Heart Lung Transplant (2009) 0.85
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Telemonitoring in patients with heart failure. N Engl J Med (2010) 10.82
Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science (2005) 8.20
Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75
Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA (2007) 7.12
Trends in survival after in-hospital cardiac arrest. N Engl J Med (2012) 5.67
Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. JAMA (2006) 5.06
Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med (2006) 4.44
Appropriateness of percutaneous coronary intervention. JAMA (2011) 4.33
Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA (2009) 4.24
Serum potassium levels and mortality in acute myocardial infarction. JAMA (2012) 4.09
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail (2009) 3.95
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol (2013) 3.90
Long-term outcomes in elderly survivors of in-hospital cardiac arrest. N Engl J Med (2013) 3.85
Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation (2012) 3.61
Automated external defibrillators and survival after in-hospital cardiac arrest. JAMA (2010) 3.36
Hospital-wide code rates and mortality before and after implementation of a rapid response team. JAMA (2008) 3.30
Hospital variation in time to defibrillation after in-hospital cardiac arrest. Arch Intern Med (2009) 3.27
Contraindicated initiation of β-blocker therapy in patients hospitalized for heart failure. JAMA Intern Med (2013) 3.26
Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation (2008) 3.19
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA (2005) 3.16
Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol (2002) 3.05
The concept of risk in comparative-effectiveness research. N Engl J Med (2014) 3.04
Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev (2006) 2.99
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation (2005) 2.85
Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 2.83
Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH): design and rationale of a prospective multicenter registry. Circ Cardiovasc Qual Outcomes (2011) 2.77
Racial differences in survival after in-hospital cardiac arrest. JAMA (2009) 2.65
Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. J Am Coll Cardiol (2010) 2.62
Concordance of physician ratings with the appropriate use criteria for coronary revascularization. J Am Coll Cardiol (2011) 2.62
Measuring performance for treating heart attacks and heart failure: the case for outcomes measurement. Health Aff (Millwood) (2007) 2.62
The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. J Am Coll Cardiol (2012) 2.50
Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol (2010) 2.49
Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA (2009) 2.42
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol (2006) 2.41
All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. J Am Coll Cardiol (2009) 2.40
Health care insurance, financial concerns in accessing care, and delays to hospital presentation in acute myocardial infarction. JAMA (2010) 2.33
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol (2005) 2.31
Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction. Arch Intern Med (2011) 2.29
Clinical features and outcomes of carotid artery stenting by clinical expert consensus criteria: a report from the CARE registry. Catheter Cardiovasc Interv (2010) 2.21
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Predictors of smoking cessation after a myocardial infarction: the role of institutional smoking cessation programs in improving success. Arch Intern Med (2008) 2.16
Disease-specific health status as a predictor of mortality in patients with heart failure: a systematic literature review and meta-analysis of prospective cohort studies. Eur J Heart Fail (2014) 2.13
American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. Circulation (2005) 2.10
Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol (2011) 2.06
Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv (2009) 2.03
Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J (2011) 2.00
Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol (2006) 1.98
Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention. Circ Cardiovasc Qual Outcomes (2009) 1.89
Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med (2012) 1.89
Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes (2011) 1.88
Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA (2011) 1.88
Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). J Am Coll Cardiol (2013) 1.86
Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J Am Coll Cardiol (2003) 1.85
Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. Am Heart J (2012) 1.84
Omega-6 and trans fatty acids in blood cell membranes: a risk factor for acute coronary syndromes? Am Heart J (2008) 1.83
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation (2009) 1.82
The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int (2011) 1.79
Exploring patients' reasons for discontinuance of heart medications. J Cardiovasc Nurs (2009) 1.78
Careers in cardiovascular outcomes research. Circulation (2009) 1.78
Financial barriers to health care and outcomes after acute myocardial infarction. JAMA (2007) 1.73
Cardiovascular health: the importance of measuring patient-reported health status: a scientific statement from the American Heart Association. Circulation (2013) 1.73
Glucose normalization and outcomes in patients with acute myocardial infarction. Arch Intern Med (2009) 1.73
Delay from symptom onset to hospital presentation for patients with non-ST-segment elevation myocardial infarction. Arch Intern Med (2010) 1.73
Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol (2013) 1.72
Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease. Circ Cardiovasc Genet (2011) 1.69
Surgical candidacy and selection biases in nonemergent left main stenting: implications for observational studies. JACC Cardiovasc Interv (2011) 1.68
Quantifying improvement in symptoms, functioning, and quality of life after peripheral endovascular revascularization. Circulation (2007) 1.67
A validated prediction tool for initial survivors of in-hospital cardiac arrest. Arch Intern Med (2012) 1.64
Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation (2004) 1.63
Drug-eluting stents and the use of percutaneous coronary intervention among patients with class I indications for coronary artery bypass surgery undergoing index revascularization: analysis from the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv (2009) 1.62
The elderly: health status benefits and recovery of function one year after coronary artery bypass surgery. J Am Coll Cardiol (2003) 1.62
Testing the performance of the ENRICHD Social Support Instrument in cardiac patients. Health Qual Life Outcomes (2004) 1.61
"I'm not just a heart, I'm a whole person here": a qualitative study to improve sexual outcomes in women with myocardial infarction. J Am Heart Assoc (2013) 1.60
Resistant hypertension. BMJ (2012) 1.58
Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol (2011) 1.58
The relationship between B-type natriuretic peptide and health status in patients with heart failure. J Card Fail (2005) 1.58
Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial. Circ Cardiovasc Interv (2011) 1.56
Mayo Clinic Risk Score for percutaneous coronary intervention predicts in-hospital mortality in patients undergoing coronary artery bypass graft surgery. Circulation (2008) 1.56